Anti-CTLA4 Therapy: Benefits and Risks
One of the most significant clinical advances in cancer immunotherapy to date has been the targeting of the immune "checkpoints" that inhibit effector T-cell function. Cytotoxic T lymphocyte-associated protein 4 (CTLA4), which was one among the first checkpoint regulators to be characterized, is transiently expressed by activated effector T cells and constitutively expressed on regulatory T cells (Tregs).
1 CTLA4 inhibits T cells by at least 2 mechanisms: (1) by preferentially binding CD80 or CD86 on antigen-presenting cells (APCs), thereby antagonizing the co-stimulatory signals delivered to T cells via CD28; 2 and (2) by sending an anergy-inducing signal via the intracellular kinases phosphoinositide-3-kinase (PI3K) and AKT1 (also known as protein kinase B, PKB). 3 Systemic CTLA4 blockade confers antitumor immunity in murine models 4 and improves the overall survival of melanoma patients, 5 but is associated with dose-dependent and occasionally fatal autoimmune toxicities, including pneumonitis, enterocolitis, and hepatitis 6 . An approach that maximizes the activation of antitumor T cells while keeping T lymphocytes specific for self structures at bay would increase the benefit-to-risk ratio of this form of immunotherapy and provide immediate advantage to cancer patients.
Local Anti-CTLA4 Therapy, Could it Work?
Recent studies by Marabelle et al. 7 and Fransen et al. 8 The question addressed by Marabelle et al. and Fransen et al. is whether (and how) the in vivo manipulation of TILs at one tumor site might induce a similarly potent activation and render them resistant to immunosuppression (Fig. 1) . The local blockade of CTLA4 rendered effector T cells resistant to the immunosuppressive activity of Tregs in vitro. 10, 11 If this finding extended to an in vivo setting, then the blockade of CTLA4 at one "priming" tumor site would render T cells insensitive to Treg-dependent immunosuppression at distant sites. Additional signals could be required to achieve such a priming, and activated APCs might constitute a rich source of these signals, including T H 1-priming cytokines such as interleukin (IL)-12 and IL-18, we well as co-stimulatory ligands like CD80, CD86 and tumor necrosis factor (ligand) superfamily, member 4 (TNFSF4, best known as OX40 ligand). For example, it has been shown that the ligation of tumor necrosis factor receptor superfamily, member 4 (TNFRSF4, best known as OX40) by agonist antibodies disables Treg 12 and downregulates the expression of CTLA4 on effector T cells. 13 Presumably, these OX40-targeting antibodies mimic the signal normally provided by the OX40L molecules expressed by activated dendritic cells (DCs). Similarly, lipid-based adjuvants such as Montanide 14 have been shown to enhance the activation of cytotoxic T lymphocytes (CTLs), 15 antibodies in Montanide induces systemic antitumor immunity as effectively as the systemic administration of the same molecules at standard doses. In both models, the induction of CD8 + T cells specific for a tumor-associated antigen (i.e., ovalbumin) and the dependence of antitumor immunity upon the CD8 + T-cell population as a whole were demonstrated. Additionally, both studies showed that the local delivery of low-dose anti-CTLA4 antibodies yields significantly (i.e., 1000-fold) lower levels of serum antibodies than the systemic administration, and that this immunotherapeutic paradigm is effective against other tumor types (i.e., breast adenocarcinoma and T-cell lymphoma). These pre-clinical findings have prominent clinical implications given the dose-dependent side effects documented in cancer patients receiving anti-CTLA4 antibodies systemically.
Local anti-CTLA4 Therapy is Not Enough -ModelDependent Differences
Though both the studies by Marabelle et al. and Fransen et al. demonstrated that the local administration of anti-CTLA4 antibodies at low doses exerts antineoplastic effects, the co-delivery of CTLA4-targeting antibodies with Montanide was as effective as the systemic approach, while the combination of anti-CTLA4 antibodies with CpG ODNs and anti-OX40 antibodies achieved superior efficacy as compared with the systemic administration. The studies also highlighted notable mechanistic differences. Marabelle et al. demonstrated indeed that the intratumoral injection of anti-CTLA4 antbiodies, anti-OX40 antibodies and CpG ODNs depletes tumor-resident Tregs (including tumor-specific Trefs), a process that is accompanied by the accumulation of both CD4
+ and CD8 + effector T cells that mediate anticancer immune responses. By contrast, Fransen et al. showed that local delivery of CTLA4-targeting antibodies induces a tumorspecific immune response that relies upon CD8
+ but not CD4 + cells. These discrepancies may originate from the therapeutic regimens or reflects variables in the model system employed, including tumor type or injection site (i.e., intratumoral vs. peritumoral). Favoring the former possibility, another group has shown that the intratumoral delivery of anti-CTLA4 antibodies did not deplete tumor-resident Tregs, but only did so when combined with anti-CD25 antibodies. 19 These findings suggest that the local blockade of CTLA4 as a standalone immunotherapeutic intervention is insufficient to induce systemic immune responses against all tumor types.
Local Anti-CTLA4 Treatment in the Clinic
The promising pre-clinical results and practical elegance of these novel efforts to increase both the efficacy and safety of anticancer immunotherapy have prompted several clinical trials testing variations thereof. A study of intratumoral ipilimumab combined with local radiotherapy in patients with melanoma, lymphoma, or colorectal cancer (NCT01769222) has recently been initiated in Stanford (California). This approach may harness the capacity of radiotherapy to promote the exposure of the endoplasmic reticulum protein calreticulin to the cell membrane and induce immunogenic cell death. 20 An alternate approach being evaluated at the Huntsman Cancer Institute (Salt Lake City, Utah) is the intratumoral injection of interleukin-2 (IL-2) plus ipilimumab in patients with unresectable melanoma (NCT01672450). In this setting, targeting CTLA4 might counteract the proliferative effect of high local IL-2 concentrations on Tregs 21 or skew the microenvironment toward the proliferation of TILs, hence inducing systemic antitumor immune responses. The results of this study may serve as an interesting counterpoint to a related approach currently being investigated in Tübingen (Germany). In this setting, intratumoral IL-2 is combined with systemic ipilimumab (at standard dosing) (NCT01480323). Cumulatively, these studies will allow for assessing the safety and efficacy of IL-2 at intratumoral doses ranging from 3.3% to 67% of standard systemic regimens.
Overall, the translation-minded rationale and impressive pre-clinical science behind these studies represent a meaningful progress in the field of applied oncoimmunology. This progress sits atop our decision tree of possible immunotherapeutic combinations, weighing down the branches and bringing some fruitful results within reach, which will be real, near-term benefits to cancer patients.
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